KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Gross Profit (2017 - 2025)

Historic Gross Profit for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $5.1 billion.

  • Takeda Pharmaceutical's Gross Profit rose 1674.96% to $5.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $31.7 billion, marking a year-over-year increase of 738.21%. This contributed to the annual value of $5.4 billion for FY2025, which is 7260.63% down from last year.
  • Takeda Pharmaceutical's Gross Profit amounted to $5.1 billion in Q4 2025, which was up 1674.96% from $15.8 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Gross Profit registered a high of $15.8 billion during Q3 2025, and its lowest value of $4.4 billion during Q4 2024.
  • In the last 5 years, Takeda Pharmaceutical's Gross Profit had a median value of $5.3 billion in 2023 and averaged $6.8 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Gross Profit tumbled by 7028.03% in 2021, and later soared by 20391.0% in 2022.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Gross Profit stood at $5.5 billion in 2021, then dropped by 15.71% to $4.6 billion in 2022, then fell by 1.57% to $4.5 billion in 2023, then fell by 2.77% to $4.4 billion in 2024, then grew by 16.75% to $5.1 billion in 2025.
  • Its last three reported values are $5.1 billion in Q4 2025, $15.8 billion for Q3 2025, and $5.4 billion during Q2 2025.